# Cryo Cell International Inc: Form 10-Q for the period ended May 31, 2016

- Company: [Cryo Cell International Inc](/companies/ccel.md) (CIK 862692)
- Form: 10-Q
- Filed: 2016-07-11
- Accepted by EDGAR: Jul 11, 2016, 21:29 ET
- Period: 2016-05-31
- Accession: 0001193125-16-645605
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/862692/000119312516645605/d122646d10q.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/862692/000119312516645605/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2016-05-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2016-03-01 to 2016-05-31 | $5.8m | us-gaap:Revenues |
| Revenue | 6 months, 2015-12-01 to 2016-05-31 | $10.9m | us-gaap:Revenues |
| Cost of revenue | 3 months, 2016-03-01 to 2016-05-31 | $1.4m | us-gaap:CostOfServices |
| Cost of revenue | 6 months, 2015-12-01 to 2016-05-31 | $2.8m | us-gaap:CostOfServices |
| Research and development | 3 months, 2016-03-01 to 2016-05-31 | $12.0k | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months, 2015-12-01 to 2016-05-31 | $20.7k | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months, 2016-03-01 to 2016-05-31 | $3.4m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 6 months, 2015-12-01 to 2016-05-31 | $7.0m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months, 2016-03-01 to 2016-05-31 | $882.4k | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months, 2015-12-01 to 2016-05-31 | $1.0m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2016-03-01 to 2016-05-31 | $343.5k | us-gaap:InterestExpense |
| Interest expense | 6 months, 2015-12-01 to 2016-05-31 | $604.8k | us-gaap:InterestExpense |
| Income tax | 3 months, 2016-03-01 to 2016-05-31 | $201.7k | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months, 2015-12-01 to 2016-05-31 | $201.7k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2016-03-01 to 2016-05-31 | $637.1k | us-gaap:NetIncomeLoss |
| Net income | 6 months, 2015-12-01 to 2016-05-31 | $514.2k | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2016-03-01 to 2016-05-31 | $0.07 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months, 2015-12-01 to 2016-05-31 | $0.06 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2016-03-01 to 2016-05-31 | $0.07 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months, 2015-12-01 to 2016-05-31 | $0.06 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2016-03-01 to 2016-05-31 | 9,397,230 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months, 2015-12-01 to 2016-05-31 | 9,336,538 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months, 2015-12-01 to 2016-05-31 | $1.3m | us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations |
| Capital expenditure | 6 months, 2015-12-01 to 2016-05-31 | $292.2k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Share repurchases | 6 months, 2015-12-01 to 2016-05-31 | $443.2k | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | at 2016-05-31 | $4.5m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2016-05-31 | $11.1m | us-gaap:AssetsCurrent |
| Total assets | at 2016-05-31 | $20.5m | us-gaap:Assets |
| Current liabilities | at 2016-05-31 | $10.5m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2016-05-31 | $25.1m | us-gaap:Liabilities |
| Long-term debt | at 2016-05-31 | $2.3m | us-gaap:LongTermDebtNoncurrent |
| Shareholders' equity | at 2016-05-31 | −$4.6m | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 33,251 characters.

### Forward Looking Statements

This Form 10-Q, press releases and certain information provided periodically in writing or orally by the Company’s officers or its agents may contain statements which constitute “forward-looking statements”. The terms “Cryo-Cell International, Inc.,” “Cryo-Cell,” “Company,” “we,” “our” and “us” refer to Cryo-Cell International, Inc. The words “expect,” “anticipate,” “believe,” “goal,” “strategy,” “plan,” “intend,” “estimate” and similar expressions and variations thereof, if used, are intended to specifically identify forward-looking statements. Those statements appear in a number of places in this Form 10-Q and in other places, and include statements regarding the intent, belief or current expectations of the Company, its directors or its officers with respect to, among other things:

(i) our future performance and operating results;

(ii) our future operating plans;

(iii) our liquidity and capital resources; and

(iv) our financial condition, accounting policies and management judgments.

Investors and prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those projected in the forward-looking statements as a result of various factors. The factors that might cause such differences include:

(i) any adverse effect or limitations caused by recent increases in government regulation of stem cell storage facilities;

(ii) any increased competition in our business including increasing competition from public cord blood banks particularly in overseas markets but also in the U.S.;

(iii) any decrease or slowdown in the number of people seeking to store umbilical cord blood stem cells or decrease in the number of people paying annual storage fees;

(iv) any new services relating to other types of stem cells that have not yet been offered commercially, and there is no assurance that other stem cell services will be launched or will gain market acceptance;

(v) any adverse impacts on revenue or operating margins due to the costs associated with increased growth in our business, including the possibility of unanticipated costs relating to the operation of our facility and costs relating to the commercial launch of new types of stem cells;

(vi) any unique risks posed by our international activities, including but not limited to local business laws or practices that diminish our affiliates’ ability to effectively compete in their local markets;

(vii) any technological or medical breakthroughs that would render our business of stem cell preservation obsolete;

(viii) any material failure or malfunction in our storage facilities; or any natural disaster or act of terrorism that adversely affects stored specimens;

(ix) any adverse results to our prospects, financial condition or reputation arising from any material failure or compromise of our information systems;

(x) the costs associated with defending or prosecuting litigation matters, particularly including litigation related to intellectual property, and any material adverse result from such matters;

(xi) the success of our licensing agreements and their ability to provide us with royalty fees;

(xii) any difficulties and increased expense in enforcing our international licensing agreements;

(xiii) any adverse performance by or relations with any of our licensees;

(xiv) any inability to enter into new licensing arrangements including arrangements with non-refundable upfront fees;

(xv) any inability to realize cost savings as a result of recent acquisitions;

(xvi) any inability to realize a return on an investment;

(xvii) any increased U.S. income tax expense as a result of inability to utilize or exhaustion of net operating losses;

(xviii) any adverse impact on our revenues and operating margins as a result of discounting of our services in order to generate new business in tough economic times where consumers are selective with discretionary spending;

(xix) the success of our global expansion initiatives;

(xx) our actual future ownership stake in future therapies emerging from our collaborative research partnerships;

(xxi) our ability to minimize our future costs related to R&D initiatives and collaborations and the success of such initiatives and collaborations;

(xxii) any inability to successfully identify and consummate strategic acquisitions;

(xxiii) any inability to realize benefits from any strategic acquisitions;

(xxiv) the Company’s ability to realize a profit on the acquisition of Prepacyte-CB;

(xxv) the costs associated with proxy contests and its impact on our business and

(xxvi) other factors many of which are beyond our control.

We undertake no obligation to publicly update or revise the forward-looking statements made in this Form 10-Q to reflect events or circumstances after the date of this Form 10-Q or to reflect the occurrence of unanticipated events.

Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect management’s analysis only as of the date hereof. Cryo-Cell International, Inc. undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof. Readers should carefully review the risk factors described in other documents the Company files from time to time with the Securities and Exchange Commission, including the Annual Report on Form 10-K filed by the Company and any Current Reports on Form 8-K filed by the Company.

### Overview

The Company’s principal sources of revenues are service fees for cord blood processing and preservation for new customers and recurring annual storage fees. Effective July 2015, the Company offers two pricing models, a standard plan and premium plan. The Company charges fees of $1,400 for the standard plan and $1,950 for the premium plan to new clients for the collection kit, processing, testing and return medical courier service, with discounts in the case of multiple children from the same family and in other circumstances. The Company charges an annual storage fee of $150 for new clients that enroll in the standard and premium plans; storage fees for existing customers depend on the contracts with such customers. The Company continues to offer a one-time payment plan for 21 years of storage and a life-time payment plan, pursuant to which the client is charged $3,799 for the standard plan and $4,249 for the premium plan and $6,000 for the standard plan and $7,000 for the premium plan, respectively, less discounts in the case of multiple children from the same family and in other circumstances. The one-time plan includes the collection kit, processing and testing, return medical courier service and 21 years of pre-paid storage fees. The life-time plan includes the collection kit, processing and testing, return medical courier service and pre-paid storage fees for the life of the client. The Company also receives other income from licensing fees and royalties from global affiliates.

On June 11, 2015, the Company entered into an Asset Purchase Agreement (the “Asset Purchase Agreement”) with CytoMedical Design Group LLC (“CytoMedical”), for the purchase of certain assets and assumption of certain liabilities and contracts that CytoMedical used in the operation of its cord blood business. The Prepacyte-CB Processing System is used in cell processing laboratories to process and store stem cells from umbilical cord blood. The purchase price was $2,400,000, plus the value of inventory, comprised of $1,553,272 in cash and assumed liabilities less any prepayment made by the Company to CytoMedical ($966,597 at closing and $586,675 on or before September 30, 2015) and a note payable to the seller in the amount of $1,300,000. The closing was effective on June 30, 2015. On April 22, 2016 the Company paid $778,287 which constituted payment in full of the Company’s payment obligations to CMDG pursuant to the terms of the original APA and Promissory Note, as well as pursuant to the terms of the Loan/Promissory Note Sale Agreement and Mutual Release executed by the Company and CMDG on April 22, 2016. The difference between the remaining principal balance and the final payment made on April 22, 2016 was $300,593 which was recorded as a gain on extinguishment of debt for the three and six months ended May 31, 2016 on the accompanying consolidated statements of comprehensive income.

During the six months ended May 31, 2016, total revenue increased 11% as compared to the same period in 2015. The Company reported net income of approximately $514,000 or $0.06 per basic common share for the six months ended May 31, 2016 compared to net income of approximately $496,000 or $0.05 per basic common share for the same period in 2015. The increase in net income for the six months ended May 31, 2016 principally resulted from the 11% increase in total revenues and the $300,593 gain on extinguishment of debt as a result of the early payoff of the loan with CMDG, as described above. This was partially offset by a 5% increase in cost of sales and an 18% increase in selling, general and administrative expenses.

At May 31, 2016, the Company had cash and cash equivalents of $4,516,162. The Company’s cash increased by $364,000 during the first six months of fiscal 2016, primarily as a result of $1.3 million of cash provided by operations offset by $516,000 of cash used to purchase property and equipment and marketable securities, $204,000 of cash provided by the redemption of a Certificate of Deposit, approximately $443,000 used for stock repurchases and approximately $876,000 used for the repayment of the Promissory Note to CMDG. On May 20, 2016, the Company entered into a Subordination Agreement with Texas Capital Bank and CrowdOut Capital LLC (“CrowdOut”) for a subordinated loan of the principal amount of $650,000, which amount CrowdOut advanced to the Company on May 20, 2016. The proceeds of the subordinated loan will be used by the Company to fund continued repurchases of the Company’s common stock.

Consistent with its fiduciary duties, the board of directors and management has reviewed and will continue to review strategic options and opportunities for the Company, in order to maximize shareholder value. These options may include, but are not limited to, strategic mergers or acquisitions, investments in other public and/or private companies, repurchases of RSA interests, a deregistration of the Company’s common stock under the Securities Exchange Act of 1934 or a going-private transaction. In order to undertake any of the aforementioned activities, the Company may take on substantial debt or equity capital which could increase the risk of investment in the Company.

### Results of Operations - Six Month Period Ended May 31, 2016 Compared to the Six Month Period Ended May 31, 2015

***Revenues.*** Revenues for the six months ended May 31, 2016 were $10,925,254 as compared to $9,857,270 for the same period in 2015, an 11% increase. The increase in revenue was primarily attributable to a 9% increase in processing and storage fees.

*Processing and Storage Fees.* The increase in processing and storage fee revenue is attributable to a 1% increase in domestic recurring annual storage fee revenue and a 9% increase in the number of new cord blood specimens processed in the first six months of fiscal 2016 versus the same period in 2015.

*Product Revenue*. On June 11, 2015, the Company entered into an Asset Purchase Agreement as described in Note 2 of the Company’s financial statements. For the six months ended May 31, 2016, revenue from the product sales was $198,118 compared to $0 for the six months ended May 31, 2015.

*Licensee and Royalty Income.* Licensee and royalty income for the six months ended May 31, 2016, was $356,932 as compared to $338,824 for the 2015 period. Licensee and royalty income for the six months ended May 31, 2016 and May 31, 2015 consists of royalty income earned on the processing and storage of specimens in India where the Company has a definitive License and Royalty Agreement.

The Company changed the methodology used to record the processing and storage royalty income during the fourth quarter of fiscal year 2015 from recognizing royalty income based on historical estimates of specimens processed and stored to utilizing actual specimens processed and stored. The Company accounted for this change as a change in accounting estimate.

Per the License and Royalty Agreement with Lifecell, there is a $1,000,000 cap on the amount of royalties due to the Company per year and a $10,000,000 cap on the amount of royalties due to the Company for the term of the License and Royalty Agreement. The cap(s) are calculated based on Lifecell’s fiscal year end, March 31st. As of the end of the Company’s fiscal year ended November 30, 2015, Lifecell had reached the $1 Million cap and paid the Company in full for Lifecell’s fiscal year ended March 31, 2016. As of May 31, 2016, Lifecell has paid the Company $4,100,000 for royalties due under the terms of the License and Royalty Agreement.

***Cost of Sales.*** Cost of sales for the six months ended May 31, 2016 was $2,779,391 as compared to $2,651,374 for the same period in 2015, representing a 5% increase. Cost of sales was 25% of revenues for the six months ended May 31, 2016 and 27% for the six months ended May 31, 2015. Cost of sales includes wages and supplies associated with process enhancements to the existing production procedures and quality systems in the processing of cord blood specimens at the Company’s facility in Oldsmar, Florida and depreciation expense of approximately $64,000 and $79,000 for the six months ended May 31, 2016 and 2015, respectively. Also, included in Cost of sales is $188,998 and $0 related to the costs associated with production of the Prepacyte®-CB processing and storage system for the six months ended May 31, 2016 and May 31, 2015, respectively. The increase in cost of sales for the six months ended May 31, 2016 versus May 31, 2015 is mainly due to the costs associated with Prepacyte®-CB.

***Selling, General and Administrative Expenses.*** Selling, general and administrative expenses for the six months ended May 31, 2016 were $7,002,965 as compared to $5,920,752 for the 2015 period representing an 18% increase. These expenses are primarily comprised of selling and marketing expenses, salaries and wages for personnel and professional fees. The increase in selling, general and administrative expenses is primarily due to approximately $413,000 or 16% increase in selling and marketing expenses of which $250,000 is related to the implementation of a new consumer marketing campaign and an increase of approximately $341,000 in professional fees.

***Research, Development and Related Engineering Expenses.*** Research, development and related engineering expenses for the six months ended May 31, 2016 were $20,672 as compared to $22,519 for the 2015 period. The expenses for each period primarily relate to the Company’s cord tissue service.

***Depreciation and Amortization***. Depreciation and amortization (not included in Cost of Sales) for the six months ended May 31, 2016 was $83,420 compared to $35,343 for the 2015 period.

***Interest Expense.*** Interest expense during the six months ended May 31, 2016, was $604,797 compared to $671,087 during the comparable period in 2015. Interest expense for the six months ended May 31, 2016 consists of $22,265 related to the repayment of the note payable as a result of the Asset Purchase Agreement (Note 2 and Note 6). The remaining interest expense is mainly comprised of amounts due to the parties to the Company’s revenue sharing agreements (“RSAs”) based on the Company’s storage revenue collected. Interest expense for the six months ended May 31, 2015 is mainly comprised of amounts due to the parties to the Company’s RSAs based on the Company’s storage revenue. The Company changed the methodology used to calculate the RSA payments owed to the RSA holders during the fourth quarter of fiscal year 2015 from calculating on the amount billed to customers to the amount collected from customers as noted per the RSA contracts. The Company accounted for this change as a change in accounting estimate.

***Equity in Losses of Affiliate.*** Equity in losses of affiliate was $0 for the six months ended May 31, 2016, compared to $16,496 for the 2015 period. Equity in losses of affiliate for the six months ended May 31, 2016 and May 31, 2015, is related to compensation expense for stock option awards that were granted by Saneron to certain consultants and employees.

***Gain on extinguishment of Debt.*** Gain on extinguishment of debt was $300,593 for the six months ended May 31, 2016 which is the difference between the remaining principal balance and the payment made on April 22, 2016 constituting payment in full of the Company’s payment obligations to CMDG pursuant to the terms of the original APA and Promissory Note, as well as pursuant to the terms of the Loan/Promissory Note Sale Agreement and Mutual Release executed by the Company and CMDG (see Note 6) on April 22, 2016.

***Income Taxes***. Deferred tax assets and liabilities are measured using enacted tax rates expected to be recovered or settled. The ultimate realization of our deferred tax assets depends upon generating sufficient future taxable income prior to the expiration of the tax attributes. In assessing the need for a valuation allowance, we must project future levels of taxable income. This assessment requires significant judgment. We examine the evidence related to the recent history of tax losses, the economic conditions in which we operate and our forecasts and projections to make that determination.

The Company records foreign income taxes withheld from installment payments of non-refundable up-front license fees and royalty income earned on the processing and storage of cord blood stem cell specimens in geographic areas where the Company has license agreements. The Company recorded $53,540 and $50,824 for the six months ended May 31, 2016 and May 31, 2015, respectively, of foreign income tax expense, which is included in income tax expense in the accompanying consolidated statements of comprehensive income.

U.S. income tax expense for the six months ended May 31, 2016 was $148,195. There was no U.S. income tax expense for the six months ended May 31, 2015 due to the utilization of net operating losses and foreign tax credit carryforwards, which were not previously benefited in the Company’s financial statements.

### Results of Operations - Three Month Period Ended May 31, 2016 Compared to the Three Month Period Ended May 31, 2015

***Revenues.*** Revenues for the three months ended May 31, 2016 were $5,773,056 as compared to $5,013,889 for the same period in 2015. The increase in revenue was primarily attributable to a 10% increase in processing and storage fees and a 111% increase in license and royalty income.

*Processing and Storage Fees.* The increase in processing and storage fee revenue is primarily attributable to a 14% increase in the number of new cord blood specimens processed for three months ended May 31, 2016 versus the same period in 2015.

*Product Revenue*. On June 11, 2015, the Company entered into an Asset Purchase Agreement as described in Note 2 of the Company’s financial statements. For the three months ended May 31, 2016, revenue from the product sales was $66,379 compared to $0 for the three months ended May 31, 2015.

*Licensee and Royalty Income.* Licensee and royalty income for the three months ended May 31, 2016, was $356,932 as compared to $169,412 for the 2015 period. Licensee and royalty income for the three months ended May 31, 2016 and May 31, 2015 consisted of royalty income earned on the processing and storage of cord blood stem cell specimens in India where the Company has a definitive license agreement.

The Company changed the methodology used to record the processing and storage royalty income during the fourth quarter of fiscal year 2015 from recognizing royalty income based on historical estimates of specimens processed and stored to utilizing actual specimens processed and stored. The Company accounted for this change as a change in accounting estimate.

Per the License and Royalty Agreement with Lifecell, there is a $1,000,000 cap on the amount of royalties due to the Company per year and a $10,000,000 cap on the amount of royalties due to the Company for the term of the License and Royalty Agreement. The cap(s) are calculated based on Lifecell’s fiscal year end, March 31st. As of the end of the Company’s fiscal year ended November 30, 2015, Lifecell had reached the $1 Million cap and paid the Company in full for Lifecell’s fiscal year ended March 31, 2016. As of May 31, 2016, Lifecell has paid the Company $4,100,000 for royalties due under the terms of the License and Royalty Agreement.

***Cost of Sales.*** Cost of sales for the three months ended May 31, 2016 was $1,431,000 as compared to $1,377,387 for the same period in 2015, representing an 4% increase. Cost of sales was 25% of revenues for the three months ended May 31, 2016 and 27% for the three months ended May 31, 2015. Cost of sales includes wages and supplies associated with process enhancements to the existing production procedures and quality systems in the processing of cord blood specimens at the Company’s facility in Oldsmar, Florida and depreciation expense of approximately $31,000 and $38,000 for the three months ended May 31, 2016 and 2015, respectively. Also, included in Cost of Sales is $85,730 and $0 related to the costs associated with production of the Prepacyte®-CB processing and storage system for the three months ended May 31, 2016 and May 31, 2015, respectively.

***Selling, General and Administrative Expenses.*** Selling, general and administrative expenses for the three months ended May 31, 2016 were $3,405,712 as compared to $3,006,779 for the 2015 period representing a 13% increase. Selling, general and administrative expenses is primarily comprised of expenses for selling and marketing expenses, salaries and wages for personnel and professional fees. The increase in selling, general and administrative expenses is primarily due to approximately $193,000 or 87% increase in professional fees, $134,000 or 12% increase in salaries and wages and $81,000 or 150% increase in compensation expense related to issuances of stock options.

***Research, Development and Related Engineering Expenses.*** Research, development and related engineering expenses for the three months ended May 31, 2016 were $11,988 as compared to $10,531 for the 2015 period.

***Depreciation and Amortization***. Depreciation and amortization (not included in Cost of Sales) for the three months ended May 31, 2016 was $41,872 compared to $17,101 for the 2015 period.

***Interest Expense.*** Interest expense during the three months ended May 31, 2016, was $343,463 compared to $369,801 during the comparable period in 2015. Interest expense for the three months ended May 31, 2016 consists of $7,874 related to the repayment of the note payable as a result of the Asset Purchase Agreement (Note 2 and Note 6). The remaining interest expense is mainly comprised of amounts due to the parties to the Company’s revenue sharing agreements (“RSAs”) based on the Company’s storage revenue collected. Interest expense for the three months ended May 31, 2015 is mainly comprised of amounts due to the parties to the Company’s RSAs based on the Company’s storage revenue. The Company changed the methodology used to calculate the RSA payments owed to the RSA holders during the fourth quarter of fiscal year 2015 from calculating on the amount billed to customers to the amount collected from customers as noted per the RSA contracts. The Company accounted for this change as a change in accounting estimate.

***Equity in Losses of Affiliate.*** Equity in losses of affiliate was $0 for the three months ended May 31, 2016, compared to $8,248 for the 2015 period. Equity in losses of affiliate for the three months ended May 31, 2016 and May 31, 2015 related solely to compensation expense for stock option awards that were granted by Saneron to certain consultants and employees.

***Gain on Extinguishment of Debt.*** Gain on extinguishment of debt was $300,593 for the three months ended May 31, 2016 which is the difference between the remaining principal balance and the payment made on April 22, 2016 constituting payment in full of the Company’s payment obligations to CMDG pursuant to the terms of the original APA and Promissory Note, as well as pursuant to the terms of the Loan/Promissory Note Sale Agreement and Mutual Release executed by the Company and CMDG (see Note 6) on April 22, 2016.

***Income Taxes.*** Deferred tax assets and liabilities are measured using enacted tax rates expected to be recovered or settled. The ultimate realization of our deferred tax assets depends upon generating sufficient future taxable income prior to the expiration of the tax attributes. In assessing the need for a valuation allowance, we must project future levels of taxable income. This assessment requires significant judgment. We examine the evidence related to the recent history of tax losses, the economic conditions in which we operate and our forecasts and projections to make that determination.

The Company records foreign income taxes withheld from installment payments of non-refundable up-front license fees and royalty income earned on the processing and storage of cord blood stem cell specimens in geographic areas where the Company has license agreements. The Company recorded $53,540 and $25,412 for the three months ended May 31, 2016 and 2015, respectively, of foreign income tax expense, which is included in income tax expense in the accompanying consolidated statements of comprehensive income.

U.S. income tax expense for the three months ended May 31, 2016 was $148,195. There was no U.S. income tax expense for the three months ended May 31, 2015 due to the utilization of net operating losses and foreign tax credit carryforwards, which were not previously benefited in the Company’s financial statements.

### Liquidity and Capital Resources

On May 20, 2016, the Company entered into a Subordination Agreement with Texas Capital Bank and CrowdOut Capital LLC (“CrowdOut”) for a subordinated loan of the principal amount of $650,000, which amount CrowdOut advanced to the Company on May 20, 2016. The proceeds of the subordinated loan will be used by the Company to fund continued repurchases of the Company’s common stock. Per a promissory note dated May 20, 2016 between the Company and CrowdOut, interest at 12% per annum on the principal sum of $650,000 is payable monthly with a maturity date of July 2021, at which time, the principal amount of $650,000 is payable.

Prior to the loan, the Company’s principal source of cash has been from sales of its umbilical cord blood program to customers and royalties from licensees.

At May 31, 2016, the Company had cash and cash equivalents of $4,516,162 as compared to $4,152,162 at November 30, 2015. The increase in cash and cash equivalents during the six months ended May 31, 2016 was primarily attributable to the following:

Net cash provided by operating activities for the six months ended May 31, 2016 was $1,344,826, which was primarily attributable to the Company’s operating results.

Net cash provided by operating activities for the six months ended May 31, 2015 was $1,831,689 principally due to an increase in the Company’s new clients choosing the prepaid storage plans versus the annual storage fee plan and a 6% decrease in cost of sales.

Net cash used in investing activities for the six months ended May 31, 2016 was $311,945, which was primarily attributable to the purchases of property and equipment in the amount of $292,242 and sales and purchases of marketable securities and other investments in the amount of $224,047 which were partially offset by the redemption of a Certificate of Deposit in the amount of $204,344.

Net cash used in investing activities for the six months ended May 31, 2015 was $244,472, which was primarily attributable the sales and purchases of marketable securities and other investments of $203,419.

Net cash used in financing activities for the six months ended May 31, 2016 was $668,881, which was primarily attributable to the stock repurchase plan pursuant to which the Company has repurchased 143,793 shares of the Company’s common stock for $443,207 and the repayments of the note payable with CMDG for $875,774 which was partially offset by the subordinated loan in the amount of $650,000.

Net cash used in financing activities for the six months ended May 31, 2015 was $952,463, which was primarily attributable the stock repurchase plan pursuant to which the Company has repurchased 344,026 shares of the Company’s common stock.

The Company does not have a line of credit.

The Company anticipates making discretionary capital expenditures of approximately $500,000 over the next twelve months for software enhancements and purchases of property and equipment. The Company anticipates funding future property and equipment purchases with cash-on-hand and cash flows from future operations.

On June 20, 2016, subsequent to the balance sheet date, the Company entered into a repurchase agreement of 2,179,068 shares from Ki Yong Choi and 13,416 shares from Michael Cho for $4.50 per share, $9,866,178 in the aggregate, which was funded in part with the $8.0 million term loan advanced by TCB. On May 20, 2016, TCB advanced the Company $100.00 and on July 1, 2016, TCB advanced the remaining principal amount of $7,999,900.

The subordinated loan of $650,000 received in May 2016, will also be used by the Company to fund continued repurchases of the Company’s common stock.

The Company anticipates that its cash and cash equivalents, marketable securities and cash flows from future operations will be sufficient to fund its known cash needs for at least the next 12 months. Cash flows from operations will depend primarily upon increasing revenues from sales of its umbilical cord blood and cord tissue cellular storage services and managing discretionary expenses. If expected increases in revenues are not realized, or if expenses are higher than anticipated, the Company may be required to reduce or defer cash expenditures or otherwise manage its cash resources during the next 12 months so that they are sufficient to meet the Company’s cash needs for that period. In addition, the Company may consider seeking equity or debt financing if deemed appropriate for its plan of operations, and if such financing can be obtained on acceptable terms. There is no assurance that any reductions in expenditures, if necessary, will not have an adverse effect on the Company’s business operations, including sales activities and the development of new services and technology.

### Critical Accounting Policies

This discussion and analysis of our financial condition and results of operations is based on our consolidated financial statements, which have been prepared in accordance with U.S. generally accepted accounting principles. The preparation of these financial statements requires us to make judgments, estimates, and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses and disclosures of contingent assets and liabilities. For a full discussion of our accounting policies please refer to Note 1 to the Consolidated Financial Statements included in our 2015 Annual Report on Form 10-K filed with the SEC. Our most critical accounting policies and estimates include: recognition of revenue and the related allowance for doubtful accounts, stock-based compensation, income taxes and license and revenue sharing agreements. We continually evaluate our judgments, estimates and assumptions. We base our estimates on the terms of underlying agreements, historical experience and other factors that we believe are reasonable based on the circumstances, the results of which form our management’s basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates. There have been no material changes to our critical accounting policies and estimates from the information provided in Item 7, *Management’s Discussion and Analysis of Financial Condition and Results of Operations* included in our 2015 Annual Report on Form 10-K.

### Recently Issued Accounting Pronouncements

See Note 1 to the Consolidated Financial Statements.

### Off-Balance Sheet Arrangements

The Company has no off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on its financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that is material to investors.

## Controls and procedures

As filed, 5,683 characters.

### Evaluation of Disclosure Controls and Procedures

Based on their most recent review, as of the end of the period covered by this report, the Company’s principal executive officer and principal financial officer have concluded that the Company’s disclosure controls and procedures were not effective, and that information required to be disclosed by the Company in the reports that it files or submits under the Securities Exchange Act of 1934, as amended, is accumulated and communicated to the Company’s management, including its principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure and are ineffective to ensure that such information is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms.

As previously disclosed in the Company’s 10-K filed February 29, 2016 and the Company’s 10-Q filed April 14, 2016, the Company’s principal executive officers and principal financial officer concluded that the Company’s disclosure controls and procedures and internal controls over financial reporting were not effective, due to a material weakness surrounding the Company’s identification and application of the appropriate accounting treatment for non-routine transactions and related documentation thereof. The Company’s controls over non-routine transactions were not conducive to identify certain items with sufficient precision. Management has undertaken steps to design and implement more effective internal controls, including the implementation of a review process of non-routine transactions and has engaged qualified consultants to assist the Company with the application of the appropriate accounting treatment of non-routine transactions when necessary. During the quarter ended November 30, 2015, the Company’s principal executive officers and principal financial officer concluded that the Company’s disclosure controls and procedures and internal controls over financial reporting were not effective, due to a material weakness surrounding manual controls related to storage revenue for customers that are on a payment plan. The Company’s control over the manual process was not conducive to identify the timeliness of recording the revenue. Management has undertaken steps to design and implement more effective internal controls, including the implementation of a more comprehensive review process of manual invoicing procedures. Management will address in the Company’s third quarter Form 10-Q.

The Company has not made an amended 8-K filing with respect to the Current Reports on Form 8-K that was filed on July 16, 2015 to announce the acquisition of Prepacyte. Accordingly, the Company is not deemed a timely filer. Management intends to subsequently make this amended 8-K filing to include the required pre-acquisition financial statements of Prepacyte as well as the required pro forma financial information.

### Changes in Internal Control Over Financial Reporting

The changes in the Company’s internal control over financial reporting described in the previous paragraph were implemented during the quarter ended November 30, 2015 and continued to be remediated during the quarter ended May 31, 2016.

There were no other changes in the Company’s internal controls over financial reporting during the six months ended May 31, 2016 that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.

### Limitations on the Effectiveness of Controls

Our management, including our co-CEOs and CFO, does not expect that our disclosure controls and internal controls will prevent all error and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by management or board override of the control.

The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, controls may become inadequate because of changes in conditions, or the degree of compliance with the policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.

### CEO and CFO Certifications

Appearing as exhibits 31.1, 31.2 and 31.3 to this report there are Certifications of the Co-CEOs and the CFO. The Certifications are required in accordance with Section 302 of the Sarbanes-Oxley Act of 2002 (the Section 302 Certifications). This Item of this report is the information concerning the evaluation referred to in the Section 302 Certifications and this information should be read in conjunction with the Section 302 Certifications for a more complete understanding of the topics presented.

Filed Jul 11, 2016.
Source: SEC EDGAR, the filing index for accession 0001193125-16-645605. Last ingested by Listed: Oct 24, 2026, 14:58 ET. No prices; not investment advice.
